- Home
- ORKA vs ROOT Comparison
ORKA vs ROOT Comparison
Compare ORKA & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORKA | ROOT |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ORKA | ROOT |
|---|---|---|
| Price | $30.18 | $80.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $45.22 | ★ $125.80 |
| AVG Volume (30 Days) | ★ 412.0K | 313.9K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 3.34 |
| Revenue | N/A | ★ $1,446,800,000.00 |
| Revenue This Year | N/A | $29.96 |
| Revenue Next Year | N/A | $5.89 |
| P/E Ratio | ★ N/A | $24.24 |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $5.49 | $68.08 |
| 52 Week High | $32.28 | $181.14 |
Technical Indicators
Market Signals| Indicator | ORKA | ROOT |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 50.14 |
| Support Level | $29.38 | $78.96 |
| Resistance Level | $32.28 | $87.40 |
| Average True Range (ATR) | 1.63 | 3.28 |
| MACD | -0.11 | 0.52 |
| Stochastic Oscillator | 62.17 | 39.73 |
Price Performance
Historical ComparisonAbout ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.